Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Britain Courts Anthropic Amid US Defense Department Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
STAMFORD, Conn., Aug. 03, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017, at 8:00 a.m. ET in Boston.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
